While clearly enjoying the rewards of its a strengthening oncology portfolio, AstraZeneca PLC also used its third-quarter results update 24 October to stress that its two other therapeutic pillars - respiratory and CVRM - are performing well and hold great promise.
“Yes, we are very proud of our oncology performance at AstraZeneca, but equally we’re trying to signal that AstraZeneca is...